The iQ Group Global

NEWS: OncoTEX Inc. is pleased to announce it has received licensing for a gold compound platform technology that induces the body’s immune system to destroy cancer cells.

“This technology is very novel in terms of design, approach, and potential applications. We will continue discovery research to identify a potential clinical candidate. After our evaluation, we will move our identified clinical candidate into preclinical development.” Chief Executive Officer, Dr Jonathan Arambula.

Read the full announcement here:

Gold Technology for Immune Response Cancer Therapy Licensed to OncoTEX - OncoTEX Inc. OncoTEX Inc. (OncoTEX), a US oncology company and member of The iQ Group Global portfolio, is pleased to announce it has received licensing for a gold compound platform technology that induces the body’s immune system to destroy cancer cells.